Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
6.040,04
1,10%
NASDAQ
20.031,13
1,35%
Bitcoin
98.678,17
-0,62%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ KalVista Pharmaceuticals Inc (KALV) KalVista Pharmaceuticals Inc (KALV) Notizie

KalVista Pharmaceuticals Inc

KALV
8,76
-0,07 (-0,79%)
24 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
16/12/202413:07EDGAR2Form 8-K - Current report
16/12/202413:00BWKalVista Appoints Jeb Ledell as Chief Operating Officer
10/12/202403:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202422:17EDGAR2Form 8-K - Current report
05/12/202422:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/12/202412:30BWKalVista Pharmaceuticals Reports Second Fiscal Quarter..
04/12/202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
28/11/202402:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202402:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/11/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/11/202422:39EDGAR2Form 3 - Initial statement of beneficial ownership of..
26/11/202413:06EDGAR2Form 8-K - Current report
26/11/202413:00BWKalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to..
20/11/202401:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202401:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202401:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202421:57EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202418:02EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
13/11/202418:54EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
12/11/202415:31EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
12/11/202412:30BWKalVista Pharmaceuticals to Present at Upcoming Investor..
07/11/202420:34EDGAR2Form SC 13D/A - General Statement of Acquisition of..
05/11/202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
04/11/202422:40EDGAR2Form 8-K - Current report
04/11/202413:05BWKalVista Pharmaceuticals Announces Pricing of a $55 Million..
04/11/202413:00EDGAR2Form 8-K - Current report
04/11/202413:00BWKalVista Pharmaceuticals Enters into Non-Dilutive Synthetic..
28/10/202411:30BWKalVista Pharmaceuticals Presents New Sebetralstat Data at..
18/10/202412:30BWKalVista Pharmaceuticals to Present Data at the 2024 Annual..
04/10/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202422:05EDGAR2Form 8-K - Current report
04/10/202418:29BWKalVista Pharmaceuticals Presents Sebetralstat Data at the..
02/10/202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
30/9/202412:30BWKalVista Announces the Submission of Additional Marketing..
26/9/202412:30BWKalVista Pharmaceuticals Announces Nine Abstracts Accepted..
11/9/202422:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/9/202422:32EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/9/202402:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/9/202422:39EDGAR2Form 8-K - Current report
10/9/202413:00BWKalVista Pharmaceuticals to Participate in the 2024 Cantor..
10/9/202412:30BWKalVista Appoints Brian Piekos as Chief Financial Officer
06/9/202412:30BWKalVista Pharmaceuticals Presents Sebetralstat Data at..
05/9/202422:24EDGAR2Form 8-K - Current report
05/9/202422:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/9/202412:30BWKalVista Pharmaceuticals Reports First Fiscal Quarter..
04/9/202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
03/9/202412:30BWKalVista Announces FDA Acceptance of New Drug Application..
29/8/202412:30BWKalVista Pharmaceuticals Announces Six Abstracts Accepted..
Apertura: 8,82 Min: 8,475 Max: 8,825
Chiusura: 8,83

La tua Cronologia

NASDAQ
KALV
KalVista Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network